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Introduction
Hypoxia increases the afferent discharge of the carotid chemoreceptors, causing reflex increases in ventilatory drive and efferent sympathetic nerve activity directed towards the heart, kidneys and peripheral vasculature (Guyenet, 2000; Kumar & Prabhakar, 2012) . In humans, the use of the microneurography technique to record directly the sympathetic nerve activity to skeletal muscle vasculature (MSNA) reveals that acute hypoxic exposure elicits variable but typically dose-dependent sympathoexcitation once peripheral capillary oxygen saturation (S pO 2 ) reaches <85% (breathing hypoxic gas mixtures with a fractional inspired O 2 of 0.11-0.13%; Saito et al. 1988; Rowell et al. 1989; Somers et al. 1989; Seals et al. 1991; Duplain et al. 1999) . However, such increases in MSNA are dwarfed by those elicited by chronic hypoxic exposure, which can reach ß300% above sea-level values, despite reductions in S pO 2 being equivalent (Hansen & Sander, 2003) . The mechanism for this difference is unclear, which is unfortunate because similar mechanisms might be important for the pathophysiology of a variety of disease states characterized by chronic sympathoexcitation and chronic intermittent or sustained hypoxaemia [e.g. sleep apnoea-related hypertension (Carlson et al. 1993; , chronic obstructive pulmonary disease (Heindl et al. 2001) and chronic heart failure (Leimbach et al. 1986; ].
After acclimatization to high altitude there is an augmentation of the ventilatory response to hypoxia that has been ascribed to a sensitization of peripheral chemoreceptors (Forster et al. 1971) . Ventilatory and sympathetic chemoreflexes share common afferent pathways, and the central neurocircuitry responsible for the efferent activation of the phrenic and sympathetic nerves acts in parallel (Guyenet, 2000; Kumar & Prabhakar, 2012) . For example, denervation of the carotid body markedly reduces the increases in ventilation and renal sympathetic nerve activity induced by hypoxia in rabbits with pacing-induced congestive heart failure (Marcus et al. 2014) . However, it has been suggested that a peripheral chemoreceptor mechanism only modestly contributes to the increase in MSNA accompanying chronic exposure to high-altitude hypoxia. Indeed, Hansen & Sander (2003) observed that breathing 100% oxygen after 4 weeks at 5260 m slightly reduced MSNA (by 7 bursts min −1 ), but it still remained robustly elevated (41 bursts min −1 ) compared with sea-level values (16 bursts min −1 ). As acknowledged by the investigators, oxygen administration may have led to a reduction in ventilation and an increase in arterial CO 2 , which in turn could have attenuated the sympathoinhibitory effects of pulmonary stretch reflex engagement and increased central chemoreflex activation. Hyperoxia also has non-specific effects and can cause peripheral vasoconstriction in some individuals (Crawford et al. 1997) . Taken together, these factors suggest that the contribution of the peripheral chemoreceptors to the control of MSNA in hypoxia warrants further consideration. Chemoreceptor signalling within the carotid and aortic bodies involves a plethora of excitatory (e.g., adenosine, ATP, acetylcholine and endothelin) and inhibitory neurotransmitters (Lazarov et al. 2009) . Dopamine is one of these primary signalling molecules and has an inhibitory effect on high-affinity D 2 autoreceptors (D 2 R) located on type 1 glomus cells (Gonzalez et al. 1994) . Intracarotid infusion of dopamine inhibits chemoreceptor afferent activity in dogs (Bisgard et al. 1979) , and systemic administration of low-dose dopamine (i.e. <3 μg kg −1 min −1 ) is an established method of acutely reducing the responsiveness of the carotid chemoreceptors in humans (Boetger & Ward, 1986; Dahan et al. 1996; Limberg et al. 2016) . One study suggests that the suppressive effects of dopamine on the hypoxic ventilatory response are unaltered after individuals have been exposed to isocapnic hypoxia for 8 h (Pedersen et al. 1999) . However, ventilatory acclimatization is not complete in humans after 8 h (Dempsey & Forster, 1982) , and the effect of low-dose dopamine on the ventilatory response to acute hypoxia after more prolonged high-altitude exposure in humans remains unexamined.
The purpose of the present study was to determine whether elevations in steady-state MSNA and ventilation are reduced after 15-17 days of exposure to high-altitude hypoxia (3454 m; i.e. ambient air breathing) by I.V. infusion of low-dose dopamine (aim 1). We also determined whether the MSNA and ventilatory responses to an acutely administered incremental hypoxia test were attenuated after I.V. dopamine infusion (aim 2) and whether the magnitude of any such inhibitory effect was altered after 15-17 days of exposure to high-altitude hypoxia (aim 3). We tested the hypothesis that I.V. dopamine would reduce MSNA and ventilation both at high altitude with ambient air breathing and during an acute incremental hypoxia test, and that the inhibitory effects of dopamine during the incremental hypoxia test would be augmented at high altitude.
Methods

Ethical approval
The experiments were undertaken in accordance with the Declaration of Helsinki, except for registration in a database, and were approved by the Ethical Committee of the Swiss Federal Institute of Technology Zurich (EK 2011-N-51) . Written informed consent to take part was obtained from all participants after they had received a detailed verbal and written explanation of the study procedures.
Participant characteristics
Nine healthy individuals [mean (SD); 26 (4) years old, 179 (9) cm, 75 (10) kg, one woman] participated in this study. No participant had a medical history of cardiovascular, respiratory or neurological disease, and no participant slept higher than 2500 m in the 3 months before the start of the study. Abstinence from caffeine, alcohol and exercise was requested for the 12 h before experimental sessions.
Experimental measures
Participants rested in semi-recumbent position while continuous recordings of MSNA, respiratory and cardiovascular variables were made. Heart rate (HR) was monitored using a lead II ECG (BioAmp; ADInstruments, Bella Vista, NSW, Australia). Mean arterial pressure (MAP) and stroke volume (SV) were recorded on a beat-to-beat basis via finger photoplethysmography (Nexfin; Bmeye BV, Amsterdam, The Netherlands; Bogert et al. 2010) . Peripheral capillary oxygen saturation (S pO 2 ) was determined using finger pulse oximetry. However, owing to technical issues, the data for steady-state S pO 2 data are presented for n = 6 participants and acute incremental hypoxia test S pO 2 data are presented for n = 7 participants. Participants breathed through a mouthpiece whilst wearing a nose-clip, and minute ventilation (V E ), tidal volume (V T ), respiratory frequency (f R ) and the partial pressures of end-tidal oxygen (P ET,O 2 ) and carbon dioxide (P ET,CO 2 ) were measured breath by breath (Cosmed Quark b2, Rome, Italy). Multiunit recordings of MSNA were obtained (FE185 NeuroAmp EX; ADInstruments) from the peroneal nerve using tungsten microelectrodes (FHC, Bowdoin, ME, USA; Adlan et al. 2017) . A reference electrode was inserted S.C. 2-3 cm away from the recording electrode, which was selectively inserted into a sympathetic nerve fascicle. Neural signals were amplified (×100,000), filtered (100 Hz high pass, 2000 Hz low pass), rectified and integrated (absolute value, time constant decay 0.1 s) to obtain a mean voltage sympathetic neurogram. An acceptable MSNA recording exhibited the following characteristics: displayed a pulse-synchronous bursts pattern; had a signal-to-noise ratio of >3:1; was increased during an end-expiratory breath-hold or Valsalva manoeuvre; and was unresponsive to an unexpected loud noise or skin stroking.
Experimental protocol
Each individual participated in two experimental sessions; the first was conducted in Zurich, Switzerland (SL; 432 m) and the other at the high-altitude Jungfraujoch research station (ALT; 3454 m), 15-17 days after arrival. Participants were familiarized with the study procedures before collection of study data. At both research sites, after instrumentation and acquisition of an acceptable MSNA signal, the stability of the recording was verified for ß10 min. The experimental protocol then commenced with the collection of 5 min of eupnoea baseline data (SL-baseline, ALT-baseline; i.e. ambient air breathing). The SL-baseline was then followed by the addition of supplemental CO 2 to the inspired air in order to increase P ET,CO 2 by 2 mmHg (Altitrainer; Smtec, Nyon, Switzerland). A 3 min period was permitted to allow a new steady state to be established (stage 1), after which the incremental hypoxia test commenced (stages 2-8). First, P ET,O 2 was reduced to 75 mmHg for 3 min, and then incrementally reduced by a further 5 mmHg every 3 min until it reached 45 mmHg, while P ET,CO 2 remained clamped at +2 mmHg throughout, following the modified methods of Mou et al. (1995) . At high altitude, the ALT-baseline was followed by the addition of supplemental CO 2 and O 2 to the inspired air to increase P ET,O 2 and P ET,CO 2 to the SL-baseline levels (stage 1). A 3 min period was permitted to allow a new steady state to be established, after which the incremental hypoxia test (stages 2-8) was repeated using the P ET,O 2 and P ET,CO 2 values observed at SL as a target.
Both at SL and at high altitude, the protocols described above were repeated during the continuous infusion of dopamine into the antebrachial vein at a rate of 3 μg kg −1 min −1 in accordance with several previous studies in humans (Boetger & Ward, 1986; Dahan et al. 1996; Limberg et al. 2016) . Dopamine infusion was commenced a minimum of 10 min before any data collection. Termination criteria for dopamine infusions were as follows: signs of poor perfusion (cyanosis or pallor); technical difficulties in monitoring ECG or systolic blood pressure; subject's desire to stop; ST elevation (ࣙ1.0 mm, in leads other than V1 or aVR); sustained ventricular tachycardia; arrhythmias other than sustained ventricular tachycardia (including multifocal premature ventricular complexes, triplets of premature ventricular complexes, supraventricular tachycardia, heart block or bradyarrhythmias); chest pain; or systolic blood pressure >250 mmHg. Termination criteria were not met on any occasion.
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Data analysis
Data were acquired using the Powerlab 16/35 data acquisition system and Labchart Pro software (ADInstruments). The ECG, MAP, SV and S pO 2 were sampled at 1000 Hz and raw MSNA was sampled at 20,000 Hz and stored for offline analysis (LabChart 7 Pro v7.3.5 and Powerlab; ADInstruments). Cardiac output (CO) was calculated as SV × HR, and total peripheral resistance (TPR) as MAP/CO. Sympathetic bursts were identified by a single observer (J.P.F.) using a semi-automated scoring system created using Spike2 (Cambridge Electronic Design, Cambridge, UK). The MSNA was characterized in terms of burst incidence (bursts per 100 heart beats) and burst frequency (bursts per minute). In one individual, microneurography was unsuccessful, and in another individual the MSNA recording was lost during the final stages of the acute incremental hypoxia test. As a consequence, the steady-state MSNA data are presented for n = 8 participants and acute incremental hypoxia test MSNA data are presented for n = 7 participants.
Statistics
Statistical analysis was performed using SPSS software, version 19 (SPSS Inc., Chicago, IL, USA). Physiological data were statistically analysed using repeated-measures ANOVA, with Greenhouse-Geisser corrections applied where significant violations of the sphericity assumption were detected. More specifically, to determine whether dopamine lowers steady-state MSNA and ventilation at high altitude (SL-baseline versus ALT-baseline; aim 1) a two-way repeated measures ANOVA was used, in which the factors were altitude (SL versus ALT) and infusion (saline versus dopamine), as well as the interaction between them. To determine whether dopamine lowers MSNA and ventilation during an acutely administered hypoxic test (aim 2) and whether the magnitude of this inhibitory test is augmented at high altitude (aim 3), this model was extended to a three-way repeated-measures ANOVA, additionally including the incremental hypoxia test stage (stages 1-8), as well as all two-and three-way interactions. Where the three-way interaction (altitude × infusion × stage) was not found to be significant, the approach was simplified by dividing the analysis into separate models for each altitude, each containing the infusion, hypoxia test stage and an interaction as factors. Post hoc analysis was done using Student's paired t tests with the Bonferroni correction to investigate significant main effects and interactions. Data are expressed as the mean (SD) unless otherwise stated. A value of P < 0.05 was considered statistically significant.
Results
High-altitude hypoxia, ventilation and MSNA with ambient air breathing
Sojourn to high altitude decreased P ET,O 2 [mean ± SEM, SL versus ALT: saline, 93 (2) versus 60 (4) mmHg; dopamine, 90 (5) versus 57 (2) mmHg; P < 0.001], P ET,CO 2 [saline, 40 (2) versus 31 (1) mmHg; dopamine, 41 (3) versus 32 (2) mmHg; P < 0.001) and S pO 2 [saline, 97 (1) versus 92 (2)%; dopamine, 97 (1) versus 89 (2)%; P < 0.001] and increasedV E (by ß2.5 l min −1 ; P < 0.002; Fig. 1 ). With dopamine, P ET,O 2 was slightly lower (P = 0.023) and P ET,CO 2 slightly higher (P = 0.003) compared to saline, but no altitude × infusion interaction was observed. The S pO 2 was not different with dopamine at SL (P = 0.789), whereas it was lower with dopamine at ALT (P = 0.028). TheV E was not different with dopamine (P = 0.186), and no altitude × infusion interaction was noted for any respiratory variable (Fig. 1) . Altitude increased MSNA burst frequency (by ß80%; P = 0.019), MAP (by ß12%; P = 0.002) and HR, and MSNA burst incidence [SL versus ALT: saline, 25 (16) versus 38 (11) bursts (100 heart beats) −1 ; dopamine, 26 (21) versus 40 (12) bursts (100 heart beats) −1 ; P = 0.088] tended to increase (Figs 1 and 2) . However, CO (P < 0.646), SV and TPR (P < 0.100) were not different at ALT (Fig. 3) . Dopamine infusion increased HR (P = 0.001) and CO (P < 0.001), decreased TPR (P = 0.035), but had no effect on MSNA burst frequency (P = 0.289), MSNA burst incidence (P = 0.555), MAP (P = 0.837) and SV (P = 0.119). No altitude × infusion interaction was noted for any MSNA or cardiorespiratory variable.
Acute incremental hypoxia at SL and ALT: ventilation and MSNA
During the acute incremental hypoxia test, P ET,O 2 and S pO 2 were decreased (P < 0.001) in the same stepwise manner in all conditions (Tables 1-3 ). At SL, P ET,CO 2 remained stable throughout the incremental hypoxia test (P = 0.177), and there were no differences between the saline and dopamine conditions (P = 0.523). The P ET,CO 2 was ß3 mmHg lower (P < 0.001) at ALT than at SL during the test, and although no differences were observed between the saline and dopamine conditions (P = 0.177), P ET,CO 2 decreased during stages 3 and 4 (P < 0.05 versus stage 1).
TheV E , V T and f R increased (P < 0.001) with acute incremental hypoxia at both SL and ALT, but the magnitude of this increase was greater at altitude (P < 0.001; Fig. 4 and Tables 2 and 3). At SL, dopamine did not affect the increase inV E (P = 0.298), V T (P = 0.120) and f R (0.922) with incremental hypoxia, but at ALT thė V E (P = 0.023), V T (P = 0.047) and f R (P = 0.050) were lower with dopamine. ForV E , V T and R f , no interactions were noted between infusion and incremental hypoxia test stage for either the SL or the ALT conditions.
The MSNA burst frequency increased in a similar manner during the acute incremental hypoxia test at SL (P = 0.028) and ALT (P = 0.023; Figs 5 and 6 and Tables 2 and 3). The MSNA burst frequency was higher during the incremental hypoxia test with dopamine at both SL (P = 0.051) and ALT (P = 0.015). The MAP and CO increased progressively during the incremental hypoxia test at both SL and ALT (P < 0.01), but the magnitude of this increase was greater at altitude (P < 0.001). Dopamine did not affect MAP at either SL (P = 0.590) or ALT In this individual, a low level of muscle sympathetic nerve activity (MSNA) was present at sea level, but the recording site was verified with a pronounced MSNA response to a breath hold. Note the minimal response to dopamine, but pronounced sympathoexcitation at altitude.
(P = 0.308), but it did increase CO at SL (P = 0.041). The TPR was progressively decreased (P < 0.001) with acute incremental hypoxia both at SL and at ALT. For MSNA burst frequency, MAP, CO and TPR, no interactions were noted between infusion and incremental hypoxia test stage for either the SL or the ALT conditions.
Discussion
We sought to ascertain whether the sympathoexcitation and hyperventilation associated with hypoxia are lowered at high altitude by the I.V. infusion of low-dose dopamine to attenuate carotid chemoreceptor responsiveness. The Abbreviations: HR, heart rate; MSNA, muscle sympathetic nerve activity; P ET,CO 2 , partial pressure of end-tidal carbon dioxide; P ET,O 2 , partial pressure of end-tidal oxygen; S pO 2 , peripheral capillary oxygen saturation; and SV, stroke volume. Data are expressed as means (SD).
major new findings of the present study are as follows: (i) the elevations in MSNA and ventilation observed after 15-17 days of high-altitude hypoxia (3454 m) were not reduced by I.V. dopamine infusion when participants were breathing ambient air; (ii) the magnitude of the increase in MSNA during an acute incremental hypoxia test performed at sea level and high altitude was not affected by dopamine; and (iii) ventilation was elevated during acute incremental hypoxia at high altitude compared with sea level, but was lower at high altitude with dopamine. In the following paragraphs, a context is provided for these findings in light of the relevant literature, and several important methodological considerations relating to our experimental design are discussed.
Muscle sympathetic nerve activity, hypoxia and dopamine
The carotid chemoreceptors are classically recognized for their oxygen-sensing function and consummate reflex increase in ventilation upon activation, but they also possess important autonomic cardiovascular effects with relevance for health and disease (Guyenet, 2000; Kumar & Prabhakar, 2012) . Acute hypoxia increases the afferent discharge of the carotid chemoreceptors, causing an increase in sympathetic nerve activity to several regions (Guyenet, 2000; Kumar & Prabhakar, 2012) . However, the contribution of the carotid chemoreceptors to the sympathoexcitatory effects of chronic hypoxia is more controversial. Indeed, in the present study sojourn to 3454 m for 15-17 days markedly increased steady-state J. P. Fisher and others MSNA, but this was not attenuated with dopamine administration. This supports the findings of Hansen & Sander (2003) , who observed that breathing 100% oxygen after 4 weeks at 5260 m resulted in only a minimal reduction in MSNA (from 48 to 41 bursts min −1 ). What is more, we observed that MSNA responses to acute incremental hypoxia at altitude were also unaltered with I.V. dopamine infusion. At present, the mechanisms underlying such high-altitude sympathetic hyperactivity remain obscure, and no satisfactory explanation exists. Furthermore, Hansen & Sander (2003) demonstrated that cardiopulmonary baroreceptor loading at altitude has only a minor effect on MSNA. Remaining possibilities include central changes in the long-term potentiation of sympathetic outflow (Xie et al. 2001) , attenuated central sympathoinhibitory pathways, such as nitric oxide (Ogawa et al. 1995) , and alterations in other reflex control mechanisms.
Ventilation, hypoxia and dopamine
Blockade of the D 2 receptor in rats and cats increases carotid chemoreceptor afferent activity and ventilation (Tatsumi et al. 1995; Huey et al. 2003) . Moreover, in the same species, 24-48 h of chronic hypoxia decreased carotid body dopaminergic inhibition (Tatsumi et al. 1995; Huey et al. 2003) . Domperidone infusion to block D 2 receptors likewise augmented the hypoxic ventilatory response before and after 4 h of isocapnic hypoxia in goats (Janssen et al. 1998 ) and 8 h of isocapnic hypoxia in humans (Pedersen et al. 1999) , suggesting that dopaminergic inhibitory mechanisms are preserved. It has been suggested that the magnitude of the reduction in chemosensitivity with dopamine is reflective of the baseline chemosensitivity, and thus the endogenous dopamine concentration (Ward, 1984) . As such, our finding that ventilation was lower with dopamine compared with saline administration during an acute hypoxia test after 15-17 days at high altitude could suggest that endogenous dopamine levels at the carotid chemoreceptor are decreased at altitude in humans. However, as we did not administer a D 2 receptor blockade (e.g. domperidone) we cannot provide a definitive insight into this issue. Our findings are, however, compatible with the view that dopamine is an important inhibitory neurotransmitter in the human carotid body and that the inhibitory effects of its endogenous provision evoke a more pronounced effect on ventilation during an acute hypoxia test after 15-17 days of high-altitude exposure compared with that observed at sea level. The differential effects of dopamine on the ventilatory and MSNA responses described might be attributable to the actions of distinct populations of glomus cells (Paton et al. 2013) .
Experimental considerations
The results and conclusions of the present study must be viewed in the light of several experimental considerations. Contrary to previous reports (Welsh et al. 1978; Pedersen et al. 1999) , low-dose dopamine was not found to suppress the ventilation in conditions of normoxia and acute hypoxia at SL (P = 0.186); however, P ET,CO 2 was increased and P ET,O 2 decreased with dopamine, consistent with a mild ventilatory suppression (Welsh et al. 1978) . The differences between studies might be attributable to the marked inter-individual differences in the ventilatory response to dopamine per se (Limberg et al. 2016) . In a recent report, 30% of individuals were shown to have an increase rather than a decrease in the ventilatory response to acute hypoxia with dopamine infusion at 3 μg kg −1 min −1 (Limberg et al. 2016) . Differences in the administration of hypoxia and the analytical approaches used to assess the physiological effects of hypoxia also make it challenging to compare studies using low-dose dopamine to inhibit the chemoreflex directly. We used an acute incremental hypoxia test that was administered in the form of sequential stepwise reductions in the target P ET,O 2 , following a modification of the methods of Mou et al. (1995) . An alternative approach would have been to use short, discrete, discontinuous bouts of hypoxia, in either a repeated or a stepwise manner. This would perhaps have better circumvented issues associated with potential carry-over effects between the stages of hypoxia and any hypoxic ventilatory depression (Teppema & Dahan, 2010) . It is also acknowledged that the hypoxic ventilatory response in humans can be expressed relative to S pO 2 , but owing to technical issues these data were not acquired in all participants. Nevertheless, the approach we used enabled us to control the stepwise reductions to the target P ET,O 2 consistently in all conditions. High doses of dopamine (i.e. >3 μg kg −1 min −1 ) may activate α-and β-adrenoreceptors with well-defined cardiovascular actions and can result in hypertension (Stickland et al. 2011) . At a low dose (<3 μg kg receptors in the peripheral and kidney vasculature (Clark & Menninger, 1980) . As mentioned above, the peripheral chemoreceptors also exert effects on reflex cardiovascular control (Guyenet, 2000; Kumar & Prabhakar, 2012) . In agreement with other studies (Eugene, 2016; Limberg et al. 2016) , low-dose dopamine infusion decreased TPR in the present study. Such vasodilatory actions of dopamine probably contributed to the elevation of HR and CO in steady-state conditions and during the acute incremental hypoxia test and to the elevated MSNA burst frequency during the acute incremental hypoxia test. This probably occurred via a baroreflex mechanism in order to preserve MAP, which was largely unchanged. It is acknowledged that the occurrence of such secondary compensatory haemodynamic adjustments arguably constrains the interpretation of the data generated. In addition, dopamine has been shown to have direct cardiac effects (Holmes & Fowler, 1962) , which might have contributed to the elevated HR and CO observed with dopamine infusion. The systemic administration of low-dose dopamine (i.e. 3 μg kg −1 min −1 ) was undertaken in accordance with several previous studies in humans (Boetger & Ward, 1986; Dahan et al. 1996; Limberg et al. 2016) . However, it is important to note that despite a change in the prevailing MSNA with dopamine, the responses to the acute incremental hypoxia test were unchanged (i.e. no infusion × stage interaction noted either at SL or ALT). An alternative approach would have been to administer dopamine directly into the carotid artery and/or record carotid chemoreceptor afferent nerve discharge to verify carotid body inhibition, as has been performed in dogs (Bisgard et al. 1979; Stickland et al. 2007 ), but this extremely invasive technique was unfeasible. The hypoxic pressor response was augmented at altitude, but rather than occurring via a sympathetic vasoconstrictor effect, appeared to occur secondary to an augmented increase in CO. Whether this relates to a difference in autonomic cardiac control relating to chemoreflex activation per se warrants further investigation.
We attempted to control P ET,CO 2 such that it remained at SL isocapnic conditions throughout the acute incremental hypoxia test; however, it was lower (ß3 mmHg) at altitude. Therefore, it is possible that the sympathoexcitatory and hyperventilatory responses to the test were underestimated at ALT compared with SL. However, no differences in P ET,CO 2 were noted between the saline and dopamine conditions. Ventilation was higher at high altitude when participants were breathing air with P ET,CO 2 and P ET,O 2 maintained at sea level values (Fig. 4A ) compared with when they were breathing the ambient air (i.e. poikilocapnic hypoxia). A potential explanation for this is that the supplemental CO 2 provided to the inspired air to return it to sea-level values stimulated the chemoreceptors at high altitude (e.g. because of central acid-base balance alterations; Ainslie et al. 2013) . We observed subtle differences in the MSNA responses to altitude and acute incremental hypoxia, when expressed as burst frequency (bursts per minute) or burst incidence (bursts per 100 heart beats). For example, steady-state MSNA frequency and burst incidence were both robustly elevated at altitude, but probably because of a concomitantly elevated (P = 0.088) HR. When interpreting sympathetic effects of altitude and dopamine in the present study, we have principally relied upon burst frequency data (bursts per unit time). Stroke volume and CO were monitored using finger photoplethysmography, and although this approach can reliably track changes in these parameters during laboratory-based manoeuvres (Bogert et al. 2010) , the indirect nature of this method is a potential limitation. Finally, the small sample size is a potential limitation of J. P. Fisher and others our study. Although the number of participants is similar to earlier work using a within-subject design to examine the influence of high altitude on MSNA (Hansen & Sander, 2003) , we acknowledge the potential for a type II error to have occurred.
Conclusions
In this study, we examined the effects of I.V. low-dose dopamine on neural cardiovascular control following chronic hypobaric hypoxia (15-17 days at 3454 m). Intravenous dopamine infusion did not lower the increases in MSNA at high altitude when ambient air was breathed. Furthermore, the MSNA response to an acute incremental hypoxia test was not affected by dopamine infusion either at sea level or at high altitude. These findings support the view that I.V. low-dose dopamine to attenuate the responsiveness of the carotid chemoreceptors does not diminish the sympathoexcitation of high altitude, but this should be viewed in light of the methodological considerations relating to our experimental design that are discussed above.
